AR035640A1 - Uso de inhibidores de il-18 en la fabricacion de medicamentos para el tratamiento y/o prevencion de arteriosclerosis; metodo de tratamiento o prevencion de arteriosclerosis utilizando dichos inhibidores; uso del il-18 como marcador de mala prognosis clinica en fallas cardiacas. - Google Patents

Uso de inhibidores de il-18 en la fabricacion de medicamentos para el tratamiento y/o prevencion de arteriosclerosis; metodo de tratamiento o prevencion de arteriosclerosis utilizando dichos inhibidores; uso del il-18 como marcador de mala prognosis clinica en fallas cardiacas.

Info

Publication number
AR035640A1
AR035640A1 ARP010102129A ARP010102129A AR035640A1 AR 035640 A1 AR035640 A1 AR 035640A1 AR P010102129 A ARP010102129 A AR P010102129A AR P010102129 A ARP010102129 A AR P010102129A AR 035640 A1 AR035640 A1 AR 035640A1
Authority
AR
Argentina
Prior art keywords
inhibitors
arteriosclerosis
prevention
treatment
manufacture
Prior art date
Application number
ARP010102129A
Other languages
English (en)
Original Assignee
Applied Research Systems
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems, Inst Nat Sante Rech Med filed Critical Applied Research Systems
Publication of AR035640A1 publication Critical patent/AR035640A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se trata, describe y reivindica el uso de inhibidores de IL-18 en la fabricación de medicamentos para el tratamiento y/o prevención de arteriosclerosis; método de tratamiento o prevención de arteriosclerosis utilizando dichos inhibidores; uso del IL-18 como marcador de mala prognosis clínica en fallas cardíacas. El uso que se describe y reivindica en esta solicitud está basado en el hallazgo que existe entre síndromes coronarios agudos y niveles elevados de IL-18 circulante, factores conducentes en la formación de placas ateroescleróticas, responsables de los paros cardíacos. Específicamente se trata del uso de inhibidores de la interleuquina (IL-18) inicialmente denominada interferón delta (IFN-delta) una citoquina proinflamatoria cuya inhibición es consecuente con la inhibición en el desarrollo, progresión y estabilidad de placas. Específicamente se reivindica el uso de inhibidores de IL-18 para la formulación y fabricación de medicamentos para la prevención de arteriosclerosis V. gr.: inhibidores como los anticuerpos contra IL-18 inhibidores-ICE, anticuerpos contra cualquiera de las subunidades de los receptores IL-18. También se describen y reivindican los objetos restantes mencionados en el encabezamiento.
ARP010102129A 2000-05-05 2001-05-04 Uso de inhibidores de il-18 en la fabricacion de medicamentos para el tratamiento y/o prevencion de arteriosclerosis; metodo de tratamiento o prevencion de arteriosclerosis utilizando dichos inhibidores; uso del il-18 como marcador de mala prognosis clinica en fallas cardiacas. AR035640A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00109606 2000-05-05

Publications (1)

Publication Number Publication Date
AR035640A1 true AR035640A1 (es) 2004-06-23

Family

ID=8168631

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010102129A AR035640A1 (es) 2000-05-05 2001-05-04 Uso de inhibidores de il-18 en la fabricacion de medicamentos para el tratamiento y/o prevencion de arteriosclerosis; metodo de tratamiento o prevencion de arteriosclerosis utilizando dichos inhibidores; uso del il-18 como marcador de mala prognosis clinica en fallas cardiacas.

Country Status (33)

Country Link
US (1) US20040076628A1 (es)
EP (1) EP1278540B1 (es)
JP (1) JP5122053B2 (es)
KR (2) KR20030016254A (es)
CN (2) CN1250286C (es)
AR (1) AR035640A1 (es)
AT (1) ATE395075T1 (es)
AU (2) AU2001267390B2 (es)
BG (1) BG65881B1 (es)
BR (1) BRPI0110506B8 (es)
CA (1) CA2407895C (es)
CY (1) CY1110385T1 (es)
CZ (1) CZ300792B6 (es)
DE (1) DE60134009D1 (es)
DK (1) DK1278540T3 (es)
EA (2) EA007014B1 (es)
EE (1) EE05056B1 (es)
ES (1) ES2305082T3 (es)
HK (2) HK1055681A1 (es)
HR (1) HRP20020828A2 (es)
HU (1) HU229375B1 (es)
IL (2) IL152567A0 (es)
ME (1) ME00554B (es)
MX (1) MXPA02010895A (es)
NO (1) NO329821B1 (es)
PL (1) PL209371B1 (es)
PT (1) PT1278540E (es)
RS (1) RS50926B (es)
SI (1) SI1278540T1 (es)
SK (1) SK287761B6 (es)
UA (2) UA78492C2 (es)
WO (1) WO2001085201A2 (es)
ZA (1) ZA200208228B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ520392A (en) * 2000-02-10 2005-04-29 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
DE60224004T2 (de) * 2001-01-29 2009-07-23 Laboratoires Serono S.A., Coinsins Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
DK1390070T3 (en) * 2001-05-25 2017-04-24 Ares Trading Sa Use of IL-18 inhibitors to treat or prevent CNS damage
US6797727B2 (en) 2001-07-16 2004-09-28 Transition Therapeutics Inc. Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
PT1487541E (pt) 2002-03-22 2008-12-10 Inst Nat Sante Rech Med Utilização de inibidores de il-8 para o tratamento e/ou prevenção de doenças vasculares periféricas
CN100429315C (zh) * 2003-03-11 2008-10-29 雪兰诺实验室有限公司 含有mcmv ie2启动子的表达载体
ES2384241T3 (es) 2003-05-13 2012-07-02 Merck Serono Sa Variantes activas de la proteína que fija IL-18 y usos médicos de las mismas
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
CN1997385B (zh) * 2004-04-15 2012-01-11 阿瑟拉生物技术公司 膜联蛋白v用于预防动脉血栓和斑块破裂
CN101219208B (zh) * 2005-01-04 2010-08-11 健能隆医药技术（上海）有限公司 白介素-22的医药用途
DK1885753T3 (da) 2005-06-03 2011-10-03 Ares Trading Sa Fremstilling af rekombinant II-18-proteiner
RS52273B (en) 2005-06-10 2012-10-31 Ares Trading S.A. PROCESS FOR PURIFICATION OF IL-18 BINDING PROTEIN
KR101603001B1 (ko) 2010-08-25 2016-03-11 에프. 호프만-라 로슈 아게 Il-18r1에 대한 항체 및 그의 용도
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
MD707Z (ro) * 2013-01-18 2014-07-31 Институт Зоологии Академии Наук Молдовы Metodă de identificare a secvenţelor polimorfe 4a/4b ale genei sintetazei endoteliale a oxidului nitric
WO2015032932A1 (en) 2013-09-05 2015-03-12 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
BR112017017076A2 (pt) 2015-03-05 2018-04-10 Ab2 Bio Sa inibidor de il-18, anticorpo, métodos para o tratamento de uma doença ou um distúrbio associado a il-18 em um indivíduo, para determinar a quantidade de il-18 livre em uma amostra ou in situ, para diagnosticar uma predisposição a uma doença ou um distúrbio associado a il-18, para monitorar doença residual mínima em um paciente que segue o tratamento com o inibidor de il-18 ou a composição e para prever uma resposta de um paciente a um tratamento com o inibidor de il-18 ou composição, e, kit diagnóstico para detectar il-18 livre.
CN110273591B (zh) 2019-08-13 2023-12-12 上海杉脉电子科技发展有限公司 一种单动力微型智能锁
TW202233675A (zh) 2020-10-29 2022-09-01 瑞士商諾華公司 Ｉｌ－１８拮抗劑用於治療和／或預防異位性皮炎或相關病症之用途
CN112972655A (zh) * 2021-04-16 2021-06-18 武汉大学 白细胞介素12在制备预防、缓解和/或治疗主动脉瘤药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins
KR100537558B1 (ko) * 1998-09-01 2005-12-19 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 인터류킨-18 결합 단백질

Also Published As

Publication number Publication date
YU82602A (sh) 2006-01-16
EA005410B1 (ru) 2005-02-24
HRP20020828A2 (en) 2004-12-31
ATE395075T1 (de) 2008-05-15
BG107218A (bg) 2003-06-30
ZA200208228B (en) 2005-07-27
US20040076628A1 (en) 2004-04-22
DE60134009D1 (de) 2008-06-26
BG65881B1 (bg) 2010-04-30
EA200401183A1 (ru) 2004-12-30
WO2001085201A2 (en) 2001-11-15
AU6739001A (en) 2001-11-20
SI1278540T1 (sl) 2008-10-31
UA78492C2 (en) 2007-04-10
RS50926B (sr) 2010-08-31
KR20070073989A (ko) 2007-07-10
CA2407895C (en) 2012-12-18
AU2001267390B2 (en) 2005-09-22
EP1278540A2 (en) 2003-01-29
IL152567A (en) 2010-12-30
PL365697A1 (en) 2005-01-10
EA200201175A1 (ru) 2003-04-24
CY1110385T1 (el) 2015-04-29
NO329821B1 (no) 2010-12-27
CN1841066A (zh) 2006-10-04
BRPI0110506B8 (pt) 2021-05-25
HUP0301991A2 (hu) 2003-09-29
UA87658C2 (uk) 2009-08-10
NO20025307L (no) 2002-12-18
CZ20023644A3 (cs) 2003-03-12
ME00554B (me) 2012-03-20
BR0110506A (pt) 2003-04-01
IL152567A0 (en) 2003-05-29
CZ300792B6 (cs) 2009-08-12
BRPI0110506B1 (pt) 2015-05-19
JP5122053B2 (ja) 2013-01-16
MEP64008A (en) 2011-12-20
KR100798545B1 (ko) 2008-01-28
CN1841066B (zh) 2012-08-29
CN1250286C (zh) 2006-04-12
SK15562002A3 (sk) 2003-05-02
EE200200620A (et) 2004-06-15
JP2003532685A (ja) 2003-11-05
CN1434722A (zh) 2003-08-06
HU229375B1 (en) 2013-11-28
KR20030016254A (ko) 2003-02-26
WO2001085201A3 (en) 2002-05-10
MXPA02010895A (es) 2003-03-27
PL209371B1 (pl) 2011-08-31
ES2305082T3 (es) 2008-11-01
SK287761B6 (en) 2011-09-05
EA007014B1 (ru) 2006-06-30
EP1278540B1 (en) 2008-05-14
HUP0301991A3 (en) 2006-11-28
HK1055681A1 (en) 2004-01-21
NO20025307D0 (no) 2002-11-05
CA2407895A1 (en) 2001-11-15
HK1094909A1 (en) 2007-04-13
DK1278540T3 (da) 2008-07-21
EE05056B1 (et) 2008-08-15
PT1278540E (pt) 2008-07-03

Similar Documents

Publication Publication Date Title
AR035640A1 (es) Uso de inhibidores de il-18 en la fabricacion de medicamentos para el tratamiento y/o prevencion de arteriosclerosis; metodo de tratamiento o prevencion de arteriosclerosis utilizando dichos inhibidores; uso del il-18 como marcador de mala prognosis clinica en fallas cardiacas.
UY27965A1 (es) Derivados heterocíclicos
SE8702980D0 (sv) Therapeutic use of serotonin antagonists
PE20040751A1 (es) COMPOSICION FARMACEUTICA QUE COMPRENDE DOSIS BAJAS DE UN INHIBIDOR DEL TNFalfa HUMANO
HUP0400689A2 (hu) ABCA-1 szint-emelő vegyületek
SE8602723D0 (sv) Thiazoles, their production and pharmaceutical compositions containing them
ES2159851T3 (es) Amidas de acidos aminotiofenocarboxilicos y su empleo como inhibidores de la fosfodiestearasa.
AR030190A1 (es) Una pirimidinona o una sal farmaceuticamente aceptable de la misma, composicion farmaceutica que la comprende, uso de dicho compuesto en la fabricacion de medicamentos y procedimiento para prepararlo
CO4950524A1 (es) Inhibidores de acido nitrico sintasa
TR199802505T2 (xx) Sel�ler NA+/H+ de�i�tiricisinin (NHE) bir inhibit�r�n�n bir ilac�n �retiminde kullan�m�.
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
AR067184A1 (es) Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica
MX2007005367A (es) Uso de ranolazina en combinacion con por lo menos un agente de remodelacion para revertir la remodelacion ventricular izquierda en el tratamiento de la insuficiencia cardiaca.
ES2051675T3 (es) Inhibidores de protorfirinogeno y su uso en composiciones para detectar y tratar tumores.
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
NO170332C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1-(4-hydroksy-3,5-di-tert.-butyl-benzoyl)-homopiperaziner
AR024476A1 (es) Uso de derivados de acido benzacepin-n-acetico, para la elaboracion de preparados farmaceuticos para la profilaxis y/o tratamiento de lesiones cardiacasprocedimiento para su preparacion y productos que los contienen.
NO993670L (no) Quinoksalin i trippelkombinasjon med proteaseinhibitorer og reverse transkriptaseinhibitorer som medikamenter for behandling av AIDS
BRPI0315461B8 (pt) sistema terapêutico em forma de película
MX9207557A (es) Derivados de acidos benzofuranil- y tiofenilmetiltio-alcanocarboxilicos, procedimiento para su preparacion y medicamentos que los contienen.
ES2059534T3 (es) Nuevos derivados benzopiranos antihipertensivos.
ES2124983T5 (es) Utilizacion de un antagonista de substancia p para el tratamiento de las manchas rojas cutaneas de origen neurogeno.
ME00549B (me) Upotreba inhibitora il-18 za liječenje i/ili prevenciju srčanih oboljenja
BRPI0517983A (pt) uso de corticosteróide em associação com diurético e antiácido para tratamento de estenose vascular e prevenção de reestenose vascular
ES2063172T3 (es) Sistema terapeutico superficial con una sustancia activa antineoplasica, en especial 5-fluoruracilo.

Legal Events

Date Code Title Description
FB Suspension of granting procedure